Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Andreu Pérez, Pedro ^a   Hernandez Losa, Javier ^b   Moliné, Teresa ^b   Gil, Rosa ^a   Grueso, Judit ^a   Pujol, Anna ^a   Cortés, Javier ^b   Avila, Matias A ^c   Recio, Juan A ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; B RAF KINASE; CYCLIN D1; PROTEIN KINASE B; PROTEIN S6; RAS PROTEIN; ADENOSINE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; BRAF PROTEIN, MOUSE; DRUG DERIVATIVE; NUCLEOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; TISSUE CULTURE; TUMOR XENOGRAFT; WILD TYPE; ANIMAL; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; SKIN TUMOR; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, RAS; HUMANS; MALE; MELANOMA; MICE; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SKIN NEOPLASMS; THIONUCLEOSIDES; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953125003     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-265     Document Type: Article

References (37)

1. Savarese TM, Ghoda LY, Dexter DL, Parks RE. Conversion of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-methylthioinosine to methionine in cultured human leukemic cells. Cancer Res 1983, 43(10):4699-4702.
2. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 1995, 92(14):6489-6493. 10.1073/pnas.92.14.6489, 41543, 7604019.
3. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20(16):2149-2182. 10.1101/gad.1437206, 16912270.
4. Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009, 41(8):920-925. 10.1038/ng.411, 2741419, 19578364.
5. Stevens AP, Spangler B, Wallner S, Kreutz M, Dettmer K, Oefner PJ, Bosserhoff AK. Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma. J Cell Biochem 2009, 106(2):210-219. 10.1002/jcb.21984, 19097084.
6. Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, Li T, Sodir NM, Chen YH, Josef-Lenz H, Laird PW, et al. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology 2007, 133(1):207-218. 10.1053/j.gastro.2007.03.114, 17631143.
7. Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 2002, 27(3):193-198. 10.1016/S0741-8329(02)00227-6, 12163149.
8. Mato JM, Corrales FJ, Lu SC, Avila MA. S-Adenosylmethionine: a control switch that regulates liver function. FASEB J 2002, 16(1):15-26. 10.1096/fj.01-0401rev, 11772932.
9. Law RE, Stimmel JB, Damore MA, Carter C, Clarke S, Wall R. Lipopolysaccharide-induced NF-kappa B activation in mouse 70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5'-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions. Mol Cell Biol 1992, 12(1):103-111. 364073, 1729592.
10. Ansorena E, Garcia-Trevijano ER, Martinez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC, Avila MA. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 2002, 35(2):274-280. 10.1053/jhep.2002.30419, 11826399.
11. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 2009, 4(5):e5735. 10.1371/journal.pone.0005735, 2684647, 19478948.
12. Wolford RW, Riscoe MK, Johnson L, Ferro AJ, Fitchen JH. Effect of 5'-methylthioadenosine (a naturally occurring nucleoside) on murine hematopoiesis. Exp Hematol 1984, 12(11):867-871.
13. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, Muroni MR, Calvisi DF, Carru A, Pascale RM, Feo F. 5'-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 2001, 34(3):386-394. 10.1016/S0168-8278(00)00078-7, 11322199.
14. Maher PA. Inhibition of the tyrosine kinase activity of the fibroblast growth factor receptor by the methyltransferase inhibitor 5'-methylthioadenosine. J Biol Chem 1993, 268(6):4244-4249.
15. Riscoe MK, Ferro AJ. 5-Methylthioribose. Its effects and function in mammalian cells. J Biol Chem 1984, 259(9):5465-5471.
16. Lee SH, Cho YD. Induction of apoptosis in leukemia U937 cells by 5'-deoxy-5'-methylthioadenosine, a potent inhibitor of protein carboxylmethyltransferase. Exp Cell Res 1998, 240(2):282-292. 10.1006/excr.1998.4000, 9597001.
17. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, David M. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001, 104(5):731-741. 10.1016/S0092-8674(01)00269-0, 11257227.
18. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002, 21(7):1000-1008. 10.1038/sj.onc.1205150, 11850817.
19. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009, 4(3):e47711.
20. Lopez-Fauqued M, Gil R, Grueso J, Hernandez J, Pujol A, Moline T, Recio JA. The dual PI3K/mTOR inhibitor (PI-103) promotes immunosupression, in vivo tumor growth and increases survival of sorafenib treated melanoma cells. Int J Cancer 2009,
21. Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, Garcia-Trevijano ER, Berasain C, Corrales FJ, Avila MA, Villoslada P. Methylthioadenosine reverses brain autoimmune disease. Ann Neurol 2006, 60(3):323-334. 10.1002/ana.20895, 16786535.
22. Schlenk F, Ehninger DJ. Observations on the Metabolism of 5'-Methylthioadenosine. Arch Biochem Biophys 1964, 106:95-100. 10.1016/0003-9861(64)90161-4, 14217209.
23. Kingsley-Kallesen M, Mukhopadhyay SS, Wyszomierski SL, Schanler S, Schutz G, Rosen JM. The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol 2002, 16(9):2008-2018. 10.1210/me.2002-0103, 12198239.
24. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986, 159(1):109-113. 10.1016/0003-2697(86)90314-3, 3812988.
25. Wilcoxon F. Individual Comparisons by Ranking Methods. Biometrics Bulletin 1945, 1(6):80-83.
26. Yamanaka H, Kubota M, Carson DA. Synergistic inhibition of polyamine synthesis and growth by difluoromethylornithine plus methylthioadenosine in methylthioadenosine phosphorylase-deficient murine lymphoma cells. Cancer Res 1987, 47(7):1771-1774.
27. Nishikawa S, Ueno A, Inoue H, Takeda Y. Effect of 5'-difluoromethylthioadenosine, an inhibitor of methylthioadenosine phosphorylase, on proliferation of cultured cells. J Cell Physiol 1987, 133(2):372-376. 10.1002/jcp.1041330223, 3119605.
28. Liteplo RG, Jurewicz TJ. Serum has a differential effect on DNA replication in a human melanoma cell line cultured in methionine or 5'-deoxy-5'-methylthioadenosine. Biochim Biophys Acta 1991, 1088(3):365-372.
29. Basu I, Cordovano G, Das I, Belbin TJ, Guha C, Schramm VL. A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem 2007, 282(29):21477-21486. 10.1074/jbc.M702287200, 17548352.
30. Li TW, Zhang Q, Oh P, Xia M, Chen H, Bemanian S, Lastra N, Circ M, Moyer MP, Mato JM, et al. S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells. Mol Pharmacol 2009, 76(1):192-200. 10.1124/mol.108.054411, 19372210.
31. Avila MA, Garcia-Trevijano ER, Lu SC, Corrales FJ, Mato JM. Methylthioadenosine. Int J Biochem Cell Biol 2004, 36(11):2125-2130. 10.1016/j.biocel.2003.11.016, 15313459.
32. Hevia H, Varela-Rey M, Corrales FJ, Berasain C, Martinez-Chantar ML, Latasa MU, Lu SC, Mato JM, Garcia-Trevijano ER, Avila MA. 5'-methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. Hepatology 2004, 39(4):1088-1098. 10.1002/hep.20154, 15057913.
33. Shafman TD, Sherman ML, Kufe DW. Effect of 5'-methylthioadenosine on induction of murine erythroleukemia cell differentiation. Biochem Biophys Res Commun 1984, 124(1):172-177. 10.1016/0006-291X(84)90932-X, 6497877.
34. de Ferra F, Baglioni C. Correlation between growth inhibition and presence of 5'-methylthioadenosine in cells treated with interferon. Cancer Res 1984, 44(6):2297-2301.
35. Riscoe MK, Schwamborn J, Ferro AJ, Olson KD, Fitchen JH. Inhibition of growth but not differentiation of normal and leukemic myeloid cells by methylthioadenosine. Cancer Res 1987, 47(14):3830-3834.
36. Stramentinoli G, Gennari F. Adenosine derivatives of anti- inflammatory and analgesic activity, and therapeutic composi- tions which contain them as their active principle. Stra- mentinoli patent 4,454,122. Filed: Aug 6, 1982; Issued: Jun 12, 1984
37. Moratti E. Pharmaceutical compositions containing 5_-deoxy- 5_-methylthioadenosine s-adenosylmethionine and their salts for reducing seborrhea. Moratti patent 5,753,213. Filed Mar 13, 1990; Issued May 19, 1998